New class of drug for patients with Tourette Syndrome
Emalex Biosciences Announces $250 Million Financing Round
14-Nov-2022 -
Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.Bain Capital Life Sciences led the funding round with ...
central nervous system
neurological disorders
Series D financing
+1